Blog Archives

Pioglitazone: Too often ending in bladder cancer?

 

January 14, 2017 – Is there an increased risk of bladder cancer with pioglitazone-containing medicines? Some (most) drug regulatory agencies worldwide do think so. However, the actions taken vary considerably. The example of the French ANSM (L’Agence nationale de sécurité du médicament et des produits de santé en France) is at one end of the possibilities of actions on could take.

Read more ›

Tags: , , , , , ,

Hope for patients with urothelial carcinoma: Atezolizumab (Tecentriq) approved

May 18, 2016 –  Over the last two years, biologics  targeting the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells), notably Nivolumab (Opdivo) and Pembrolizumab (Keytruda), have come to the clinic for the treatment of a selection of oncologic indications.

Read more ›

Tags: , , , , , , ,

Exciting new drug breakthrough in bladder cancer

November 27, 2014 – A drug which makes a wide range of cancers more vulnerable to the body’s immune system is “exciting” and may mark a new era, say doctors. The drug MPDL3280A strips cancer cells of the “camouflage” they use to evade attack by the immune system.

Read more ›

Tags: , , ,

Pioglitazone Containing Medicines: Ongoing Safety Review For A Potential Increased Risk of Bladder Cancer

June 20, 2011 – The American Food and Drug Administration (FDA) informed recently (on June 15, 2011) that the  use of the diabetes medication Pioglitazone [Actos] for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the drug labels for pioglitazone-containing medicines (see the graphic at left for brand names and compositions (double click the image for enlargement)).

Read more ›

Tags: , , , , , , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

Top